NCT00829088View on ClinicalTrials.gov

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2009

Study Completion Date

February 28, 2009

Conditions
Pain
Interventions
DRUG

AZD2066

1 dose oral solution

Trial Locations (1)

Unknown

Research Site, Cheshire

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00829088 - Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066 | Biotech Hunter | Biotech Hunter